
    
      OUTLINE: This is a multi-center study.

        -  Dexamethasone and antiemetic premedication1.

        -  Docetaxel: 60 mg/m2 for a 60 minute infusion day 1 of each cycle

        -  Capecitabine: 825 mg/m2 po BID Days 1-14

      Repeat every 21 days until tumor progression or toxicity that requires discontinuation of
      therapy

      Performance status: ECOG performance status 0 or 1

      Life expectancy: At least 3 months

      Hematopoietic:

        -  ANC of > 1,500/mm3

        -  Platelets > 100,000/mm3

        -  Hemoglobin > 8 gm/dl

      Hepatic:

        -  Total Bilirubin Â£ ULN

        -  Albumin > 3

        -  Maximum Alk Phos > 2.5 x < 5 x ULN

      Renal:

        -  Creatinine clearance of > 50 ml/ min (by Cockcroft-Gault)

      Cardiovascular:

        -  No decompensated congestive heart failure or active angina.

        -  Clinically significant cardiac disease not well controlled with medication (eg.
           congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias)
           or myocardial infarction in the past 12 months is not allowed.

      Pulmonary:

        -  Not specified
    
  